PRO 1286
Alternative Names: PRO-1286Latest Information Update: 27 May 2024
At a glance
- Originator ProfoundBio
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 21 May 2024 ProfoundBio has been acquired by Genmab
- 05 Apr 2024 Adverse events, pharmacokinetics and pharmacodynamics data from preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 04 Apr 2024 Preclinical trials in Solid tumours in China (Parenteral)